Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
59.66(c) 62.57(c) 65.64(c) 66.67(c) 65.39(c) Last
140 044 292 023 519 900 142 653 184 031 Volume
-1.52% +4.88% +4.91% +1.57% -1.92% Change
More quotes
Financials (€)
Sales 2017 51,7 M
EBIT 2017 -45,6 M
Net income 2017 -48,2 M
Finance 2017 252 M
Yield 2017 -
Sales 2018 47,4 M
EBIT 2018 -50,5 M
Net income 2018 -55,3 M
Finance 2018 183 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 32,2x
EV / Sales2018 36,6x
Capitalization 1 917 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
Sector
Biotechnology & Medical Research
Calendar
06/05 | 09:00amPresentation
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
05/24 MORPHOSYS AG : MorphoSys Announces That Its Licensee Janssen Reported Updates on..
05/24 DGAP-NEWS : MorphoSys Announces That Its Licensee Janssen Reported Updates on th..
05/24 MORPHOSYS AG : MorphoSys to Present at Three Upcoming Conferences
05/24 MORPHOSYS : to Present at Three Upcoming Conferences
05/24 DGAP-NEWS : MorphoSys to Present at Three Upcoming Conferences
05/19 MORPHOSYS AG : MorphoSys Announces First Results from Phase 1 Study with Lanthip..
05/19 MORPHOSYS : Announces First Results from Phase 1 Study with Lanthipeptide MOR107..
05/19 DGAP-NEWS : MorphoSys Announces First Results from Phase 1 Study with Lanthipept..
05/18 DGAP-DD : MorphoSys AG english
05/18 MORPHOSYS AG : MorphoSys to Present Clinical Data on Proprietary Programs at Upc..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/25MorphoSys AG given €68.00 PT by Berenberg Bank. buy rating.  
05/24MorphoSys AG To Present At Three Upcoming Conferences
1
05/24MorphoSys AG : MorphoSys to Present at Three Upcoming Conferences  
05/19MorphoSys AG Announces First Results From Phase I Study With Lanthipeptide MO.. 
05/19MorphoSys AG : MorphoSys Announces First Results from Phase 1 Study with Lant.. 
More tweets
Qtime:14
News from SeekingAlpha
05/06 Morphosys' (MPSYF) CEO Simon Moroney on Q1 2017 Results - Earnings Call Trans..
05/06 MorphoSys AG 2017 Q1 - Results - Earnings Call Slides
05/03 MorphoSys AG reports Q1 results
03/09 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2016 Results - Earnings Call Trans..
03/09 MorphoSys AG reports Q4 results
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 68,6 €
Spread / Average Target 5,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG34.13%2 143
INCYTE CORPORATION38.04%27 518
QUINTILES IMS HOLDINGS..11.37%18 872
LONZA GROUP AG25.78%15 703
CELLTRION, INC.--.--%10 293
SEATTLE GENETICS, INC.25.11%9 358
More Results